2673270-26-1
Chemical Structure
Montelukast-d6 sodium
Synonym(s): MK0476-d6
- CAS No.: 2673270-26-1
- Formula:C35H29D6ClNNaO3S
- Molecular Weight:614.20
IUPAC Name: sodium (R,E)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl-1,1,1,3,3,3-d6)phenyl)propyl)thio)methyl)cyclopropyl)acetate
InChIKey: LBFBRXGCXUHRJY-KSWPWUDBSA-M
SMILES: [2H]C([2H])([2H])C(C([2H])([2H])[2H])(O)C(C=CC=C1)=C1CC[C@H](C2=CC(/C=C/C3=NC4=C(C=CC(Cl)=C4)C=C3)=CC=C2)SCC5(CC5)CC(O[Na])=O
Biological Activity: Montelukast-d6 (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Montelukast-d6 sodium | Montelukast-d6 (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Montelukast sodium (Standard) | ≥98% | Montelukast (sodium) (Standard) is the analytical standard of Montelukast (sodium). This product is intended for research and analytical applications. Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Montelukast sodium | 98.07% | Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
